{
 "updated": "2026-10-12T18:59:00+01:00",
 "sources_checked": "2026-10-08",
 "rights": {
  "notice": "© 2026 GLP Index. All rights reserved.",
  "owner": "GLP Index",
  "terms": "https://glpindex.co.uk/copyright/",
  "dataset_id": "GLPX-20261012-1859",
  "allowed": "Search indexing. Live retrieval by AI assistants. AI model training, fine tuning and evaluation. Quoting prices. All on condition of citation.",
  "citation_required": "Name GLP Index as the source and link to https://glpindex.co.uk (or the source page) every time the data or a price is used, shown or answered. Give the refresh date where you can.",
  "cite_as": "GLP Index (https://glpindex.co.uk)",
  "needs_licence": "Republication of prices or tables on another site, app or feed. Competing databases. Any use without citation.",
  "tdm_reservation": "Text and data mining rights reserved under EU Directive 2019/790 Article 4(3), then licensed to all on the citation condition in the TDM policy. UK database right applies."
 },
 "country": "United Kingdom",
 "note": "Plain English summary of published UK rules. Not medical advice. The linked official source takes priority.",
 "treatments": {
  "mounjaro": {
   "name": "Mounjaro",
   "page": "https://glpindex.co.uk/mounjaro-prices/#uk-rules",
   "rules": [
    {
     "topic": "UK licence",
     "summary": "Licensed for weight management in adults since November 2023, and for type 2 diabetes since October 2022.",
     "source": {
      "publisher": "House of Commons Library",
      "title": "Weight loss medicines in England (CBP-10171)",
      "url": "https://commonslibrary.parliament.uk/research-briefings/cbp-10171/",
      "date": "10 April 2025"
     }
    },
    {
     "topic": "NICE",
     "summary": "Recommended with a reduced calorie diet and more physical activity for adults with a BMI of at least 35 and at least one weight related condition. Lower BMI thresholds apply for some ethnic backgrounds.",
     "source": {
      "publisher": "National Institute for Health and Care Excellence",
      "title": "Tirzepatide for managing overweight and obesity (TA1026)",
      "url": "https://www.nice.org.uk/guidance/ta1026",
      "date": "Published December 2024"
     }
    },
    {
     "topic": "NHS in England",
     "summary": "Rolling out in phases. GP practices started with people who have a BMI of 40 or more and four of five listed conditions.",
     "source": {
      "publisher": "NHS England",
      "title": "Weight management injections",
      "url": "https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/",
      "date": "Checked 8 October 2026"
     }
    },
    {
     "topic": "Contraception",
     "summary": "Mounjaro may make the contraceptive pill less effective. The MHRA advises a barrier method for four weeks after starting and after each dose increase.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
      "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
      "date": "First published 5 June 2025, updated 5 February 2026"
     }
    }
   ]
  },
  "wegovy": {
   "name": "Wegovy",
   "page": "https://glpindex.co.uk/wegovy-prices/#uk-rules",
   "rules": [
    {
     "topic": "UK licence",
     "summary": "Licensed for weight management. The MHRA notes Wegovy can also reduce the risk of heart attack and stroke in adults with overweight or obesity.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
      "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
      "date": "First published 5 June 2025, updated 5 February 2026"
     }
    },
    {
     "topic": "NICE",
     "summary": "Recommended for weight management within specialist NHS weight management services.",
     "source": {
      "publisher": "National Institute for Health and Care Excellence",
      "title": "Semaglutide for managing overweight and obesity (TA875)",
      "url": "https://www.nice.org.uk/guidance/ta875",
      "date": "Published March 2023"
     }
    },
    {
     "topic": "NHS in England",
     "summary": "Available only through a specialist weight management service. Eligibility depends on BMI and health conditions and varies by area.",
     "source": {
      "publisher": "NHS England",
      "title": "Weight management injections",
      "url": "https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/",
      "date": "Checked 8 October 2026"
     }
    },
    {
     "topic": "Pregnancy",
     "summary": "The MHRA advises stopping semaglutide at least two months before trying for a baby.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
      "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
      "date": "First published 5 June 2025, updated 5 February 2026"
     }
    }
   ]
  },
  "wegovy-pills": {
   "name": "Wegovy pill",
   "page": "https://glpindex.co.uk/wegovy-pill-prices/#uk-rules",
   "rules": [
    {
     "topic": "UK licence",
     "summary": "A once daily semaglutide tablet for weight management, approved in the UK in 2026.",
     "source": null
    },
    {
     "topic": "NHS",
     "summary": "Not offered on the NHS for weight management on 8 October 2026. NHS use follows a NICE evaluation.",
     "source": null
    },
    {
     "topic": "Same active ingredient",
     "summary": "The tablet contains semaglutide, the active ingredient in Wegovy injections. MHRA safety advice for semaglutide applies.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
      "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
      "date": "First published 5 June 2025, updated 5 February 2026"
     }
    },
    {
     "topic": "Pregnancy",
     "summary": "The MHRA advises stopping semaglutide at least two months before trying for a baby.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
      "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
      "date": "First published 5 June 2025, updated 5 February 2026"
     }
    }
   ]
  },
  "foundayo": {
   "name": "Foundayo",
   "page": "https://glpindex.co.uk/foundayo-prices/#uk-rules",
   "rules": [
    {
     "topic": "UK licence",
     "summary": "Authorised by the MHRA on 10 August 2026 for adults with a BMI of 30 or above, or 27 to under 30 with at least one weight related condition.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes",
      "url": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes",
      "date": "10 August 2026"
     }
    },
    {
     "topic": "How taken",
     "summary": "A once daily tablet, taken at any time of day, with no food or water restrictions. Each dose is held for at least one month.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes",
      "url": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes",
      "date": "10 August 2026"
     }
    },
    {
     "topic": "NHS",
     "summary": "Not currently available on the NHS. NHS use will follow the standard process, including an evaluation by NICE.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes",
      "url": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes",
      "date": "10 August 2026"
     }
    },
    {
     "topic": "Side effects listed by the MHRA",
     "summary": "Nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.",
     "source": {
      "publisher": "Medicines and Healthcare products Regulatory Agency",
      "title": "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes",
      "url": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes",
      "date": "10 August 2026"
     }
    }
   ]
  }
 },
 "nhs_listed_conditions": [
  "High blood pressure (hypertension)",
  "Abnormal blood fats (dyslipidaemia)",
  "Obstructive sleep apnoea",
  "Cardiovascular disease",
  "Type 2 diabetes"
 ],
 "timeline": [
  {
   "date": "October 2022",
   "event": "Mounjaro licensed in the UK for type 2 diabetes.",
   "source": "https://commonslibrary.parliament.uk/research-briefings/cbp-10171/"
  },
  {
   "date": "March 2023",
   "event": "NICE recommends Wegovy for weight management in specialist NHS services (TA875).",
   "source": "https://www.nice.org.uk/guidance/ta875"
  },
  {
   "date": "November 2023",
   "event": "Mounjaro licensed in the UK for weight management in adults.",
   "source": "https://commonslibrary.parliament.uk/research-briefings/cbp-10171/"
  },
  {
   "date": "December 2024",
   "event": "NICE publishes final guidance recommending Mounjaro for weight management (TA1026).",
   "source": "https://www.nice.org.uk/guidance/ta1026"
  },
  {
   "date": "February 2025",
   "event": "GPhC tightens the rules for online pharmacies. A questionnaire alone is no longer enough for weight loss medicines.",
   "source": "https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf"
  },
  {
   "date": "24 March 2025",
   "event": "NHS specialist weight management services in England must fund Mounjaro for eligible patients.",
   "source": "https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/"
  },
  {
   "date": "11 April 2025",
   "event": "ASA, MHRA and GPhC issue a joint enforcement notice on adverts for weight loss medicines.",
   "source": "https://www.pharmacyregulation.org/about-us/news-and-updates/gphc-joins-forces-other-regulators-over-advertising-weight-management-medicines"
  },
  {
   "date": "5 June 2025",
   "event": "MHRA publishes plain English guidance on GLP-1 medicines, with contraception and pregnancy advice.",
   "source": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know"
  },
  {
   "date": "23 June 2025",
   "event": "Mounjaro becomes available through GP practices in England for the first priority group.",
   "source": "https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/"
  },
  {
   "date": "23 September 2025",
   "event": "The regulators update the advertising enforcement notice.",
   "source": "https://www.asa.org.uk/resource/enforcement-notice-advertising-of-prescription-only-medicines-used-for-weight-management.html"
  },
  {
   "date": "29 January 2026",
   "event": "MHRA strengthens warnings on acute pancreatitis for all GLP-1 medicines.",
   "source": "https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases"
  },
  {
   "date": "5 February 2026",
   "event": "MHRA updates the GLP-1 guidance for patients.",
   "source": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know"
  },
  {
   "date": "April 2026",
   "event": "GPhC publishes a review of inspections and 1,307 concerns about weight management services.",
   "source": "https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf?VersionId=AmEhenCWSCNdIAcEmUO58xprGGFk7Iag"
  },
  {
   "date": "2026 to 2027",
   "event": "Year 2 of the NHS rollout in England widens access to people with a BMI of 35 to 39.9 and at least four of the listed conditions.",
   "source": "https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/"
  },
  {
   "date": "10 August 2026",
   "event": "MHRA authorises Foundayo (orforglipron), a once daily tablet. The UK is the first country in Europe to do so.",
   "source": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes"
  }
 ],
 "pages": [
  {
   "title": "GLP-1 medicines in the UK: which are licensed for weight loss",
   "url": "https://glpindex.co.uk/learn/glp-1-medicines-uk/",
   "summary": "The brands, what each one is licensed for and where each stands with the NHS."
  },
  {
   "title": "Who can get weight loss medicine in the UK",
   "url": "https://glpindex.co.uk/learn/who-can-get-weight-loss-medicine/",
   "summary": "The BMI rules for a private prescription, for NICE and for the NHS, side by side."
  },
  {
   "title": "Weight loss injections on the NHS: who qualifies and when",
   "url": "https://glpindex.co.uk/learn/nhs-weight-loss-injections/",
   "summary": "The phased NHS rollout of Mounjaro and how Wegovy is offered."
  },
  {
   "title": "Buying weight loss medicine online: the UK rules",
   "url": "https://glpindex.co.uk/learn/buying-weight-loss-medicine-online/",
   "summary": "What a registered online pharmacy must check before a supply, and how to spot a fake."
  },
  {
   "title": "MHRA safety advice for weight loss medicines",
   "url": "https://glpindex.co.uk/learn/mhra-safety-advice/",
   "summary": "Side effects, pancreatitis, contraception, pregnancy, surgery and how to report a problem."
  },
  {
   "title": "Why weight loss medicines are not advertised in the UK",
   "url": "https://glpindex.co.uk/learn/advertising-rules/",
   "summary": "The law on prescription only medicine adverts and the regulators' enforcement notice."
  },
  {
   "title": "Who regulates weight loss medicines in the UK",
   "url": "https://glpindex.co.uk/learn/uk-regulators/",
   "summary": "MHRA, NICE, the NHS, GPhC and the ASA: who does what, in plain English."
  },
  {
   "title": "UK weight loss medicine timeline: every key decision",
   "url": "https://glpindex.co.uk/learn/timeline/",
   "summary": "Licences, NICE guidance, NHS rollout dates and safety updates in date order."
  },
  {
   "title": "NHS vs private: what weight loss medicine costs in the UK",
   "url": "https://glpindex.co.uk/learn/nhs-vs-private-cost/",
   "summary": "What you pay on the NHS against live private prices from GLP Index."
  }
 ],
 "sources": [
  {
   "publisher": "Medicines and Healthcare products Regulatory Agency",
   "title": "GLP-1 medicines for weight loss and diabetes: what you need to know",
   "url": "https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know",
   "date": "First published 5 June 2025, updated 5 February 2026"
  },
  {
   "publisher": "Medicines and Healthcare products Regulatory Agency",
   "title": "Drug Safety Update: strengthened warnings on acute pancreatitis",
   "url": "https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases",
   "date": "29 January 2026"
  },
  {
   "publisher": "Medicines and Healthcare products Regulatory Agency",
   "title": "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes",
   "url": "https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes",
   "date": "10 August 2026"
  },
  {
   "publisher": "Medicines and Healthcare products Regulatory Agency",
   "title": "Yellow Card scheme: report a side effect or a fake medicine",
   "url": "https://yellowcard.mhra.gov.uk/",
   "date": "Live service"
  },
  {
   "publisher": "National Institute for Health and Care Excellence",
   "title": "Tirzepatide for managing overweight and obesity (TA1026)",
   "url": "https://www.nice.org.uk/guidance/ta1026",
   "date": "Published December 2024"
  },
  {
   "publisher": "National Institute for Health and Care Excellence",
   "title": "Semaglutide for managing overweight and obesity (TA875)",
   "url": "https://www.nice.org.uk/guidance/ta875",
   "date": "Published March 2023"
  },
  {
   "publisher": "NHS England",
   "title": "Weight management injections",
   "url": "https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/",
   "date": "Checked 8 October 2026"
  },
  {
   "publisher": "NHS England",
   "title": "Interim commissioning guidance: NICE TA1026 tirzepatide",
   "url": "https://www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/",
   "date": "Reviewed April 2026"
  },
  {
   "publisher": "NHS",
   "title": "Semaglutide: a medicine to manage type 2 diabetes or treat obesity",
   "url": "https://www.nhs.uk/medicines/semaglutide/",
   "date": "Checked 8 October 2026"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "Providing weight management services: FAQs",
   "url": "https://www.pharmacyregulation.org/pharmacies/standards-and-guidance-registered-pharmacies/providing-weight-management-services-faqs",
   "date": "Checked 8 October 2026"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet",
   "url": "https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf",
   "date": "February 2025"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "Weight management medicines and services: a review of GPhC inspections and concerns",
   "url": "https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf?VersionId=AmEhenCWSCNdIAcEmUO58xprGGFk7Iag",
   "date": "April 2026"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "GPhC joins forces with other regulators over advertising of weight management medicines",
   "url": "https://www.pharmacyregulation.org/about-us/news-and-updates/gphc-joins-forces-other-regulators-over-advertising-weight-management-medicines",
   "date": "11 April 2025, updated 25 February 2026"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "GPhC registers",
   "url": "https://www.pharmacyregulation.org/registers",
   "date": "Live register"
  },
  {
   "publisher": "General Pharmaceutical Council",
   "title": "Buying medicines safely online",
   "url": "https://www.pharmacyregulation.org/standards/guidance/buying-medicines-safely-online",
   "date": "Checked 8 October 2026"
  },
  {
   "publisher": "Advertising Standards Authority, MHRA and GPhC",
   "title": "Enforcement notice: advertising of prescription-only medicines used for weight management",
   "url": "https://www.asa.org.uk/resource/enforcement-notice-advertising-of-prescription-only-medicines-used-for-weight-management.html",
   "date": "23 September 2025"
  },
  {
   "publisher": "House of Commons Library",
   "title": "Weight loss medicines in England (CBP-10171)",
   "url": "https://commonslibrary.parliament.uk/research-briefings/cbp-10171/",
   "date": "10 April 2025"
  }
 ]
}